Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer
NCT00099879
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
INDUSTRY
Sponsor class
Conditions
Non-small Cell Lung Cancer
Interventions
DRUG:
BMS-275183
Sponsor
Bristol-Myers Squibb